CMS Open Payments · Program Year 2024
I/O Urology Corp.
I/O Urology Corp. reported $234,325.41 across General Payments, Research, and Ownership to 22 physicians and teaching hospitals across 25 transactions.
- $234.3K Above-median payer
- All-tracks total
- 25 Below-median volume
- Transactions
- 22 Below-median reach
- Recipients
- #961
- of 1,925 companies
I/O Urology Corp. reported $234,325.41 across all CMS Open Payments tracks (General + Research + Ownership) to 22 physicians and teaching hospitals in Program Year 2024 - ranking #961 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $2,075.41, averaging $10.7K per recipient.
How I/O Urology Corp.'s $234.3K all-tracks total breaks down
I/O Urology Corp.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
11/100
Total payments
F
12/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer i-o-urology-corp I/O Urology Corp.
$234.3K · #961/1,925 · 0.0% industry · PY2024
- TOT $234.3K
- RANK #961
- SHARE 0.0%
- TXN 25
- RCP 22
- CAT 1
- GEN $2.1K
- TOP1 14.8%
- PY 2024
Volume peers
Nearest volume peer: Ambu Inc. ($233.8K)
I/O Urology Corp. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for I/O Urology Corp.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For I/O Urology Corp., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Food and Beverage" leads the 1-category general-payment breakdown below at $2.1K (100.0% of General Payments, 22 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
I/O Urology Corp. made 1 types of general payments. "Food and Beverage" is the largest category at $2.1K, 100.0% of General Payments.
How I/O Urology Corp. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $2.1K | 22 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,289.11 (62.1%) of $2,075.41 in this company's General Payments records across 13 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for I/O Urology Corp.
The five named recipients with the highest reported General Payments from this company
- 1
Gregg Eure
$306.30 across 4 reported transactions
- 2
Lewis Kriteman
$277.66 across 2 reported transactions
- 3
Carl Capelouto
$277.66 across 2 reported transactions
- 4
Daniel Belew
$277.66 across 2 reported transactions
- 5
Paul Eber
$149.83 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
I/O Urology Corp.'s spend rank (#961 of 1,925, top 50% by spend) and concentration rank (#1,021 of 1,838, bottom 45% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- PolyMedics Innovations Inc. : $62.1K total payments, HHI 1036
- Qiagen, LLC : $659.8K total payments, HHI 1034
- Seigla Medical, Inc. : $1.1K total payments, HHI 1032
- Zimmer Biomet Holdings, Inc. : $83.9M total payments, HHI 1031
- Recor Medical Inc : $244.1K total payments, HHI 1026
- Bioprotect Medical, Inc. : $136.5K total payments, HHI 1025
- I/O Urology Corp. (this company) : $2.1K total payments, HHI 1025
- Cardinal Health 200 LLC : $63.8K total payments, HHI 1024
- Genesys Orthopedics Systems, L.L.C. : $837.2K total payments, HHI 1023
- Procyrion, Inc. : $53.4K total payments, HHI 1019
- Lupin Inc. : $30.4K total payments, HHI 1015
- Spectrum Pharmaceuticals Inc. : $38.7K total payments, HHI 1008
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as I/O Urology Corp.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about I/O Urology Corp..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with I/O Urology Corp..
Showing 6 of 1,924 companies with CMS-reported payment data.
Stability Biologics, LLC
Synthes USA Products LLC
Asensus Surgical, Inc.
Fuse Medical, Inc.
Acclarent, Inc
Put this to use
I/O Urology Corp. ranks #961 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just I/O Urology Corp.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.